
UroGen Pharma Ltd.: updates and filings
Price
$27.65
November 20, 2026Market cap $1.3B
What Ploutos Investor adds for UroGen Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Shares registered for employeesFormS-8
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 20, 2026Other material eventsForm8-K
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jun 23, 2026Change to shareholders' rights, officer or director change, shareholder voteForm8-K
- Jun 2, 2026Other material eventsForm8-K
- May 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 17, 2026Preliminary proxy statementFormPRE 14A
- Mar 2, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 2, 2026Results of operationsForm8-K
- Mar 2, 2026Material agreement entered, new material financial obligationForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 14, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | S-8 | Shares registered for employees | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 20, 2026 | 8-K | Other material events | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jun 23, 2026 | 8-K | Change to shareholders' rights, officer or director change, shareholder vote | Document |
| Jun 2, 2026 | 8-K | Other material events | Document |
| May 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 17, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 2, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 2, 2026 | 8-K | Results of operations | Document |
| Mar 2, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 14, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 4, 2016.
The full analysis
What do UroGen Pharma's filings show?
The filings are where every one of UroGen Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.